Market Cap 2.40B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 8,058,300
Avg Vol 8,703,602
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 74%
Beta 1.14
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Jul. 7 at 9:47 PM
$ABCL I believe that we will hear about the next molecule going into IND enabling studies during this meeting. So many puzzle pieces coming into place. I feel like the momentum is building and this will be a perfect time for it to continue.
0 · Reply
tranq19
tranq19 Jul. 7 at 8:47 PM
$ABCL https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Report-Second-Quarter-2026-Financial-Results-on-August-5-2026/default.aspx
0 · Reply
ETAlpha
ETAlpha Jul. 7 at 8:23 PM
$ABCL hitting the hot zone! Pullback inbound? We are straight inside the heavy resistance area at $8.46 - $10.23. The charts are screaming for a healthy breather here, so locking in partial profits at these levels makes absolute tactical sense. Don't chase it up-let the market cool down and hand us a cleaner, lower-risk buying opportunity on the next dip! Full risk management strategy and buy targets pinned on my profile.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 8:12 PM
$ABCL $ABCL is holding up surprisingly well after that big move. The stock ran hard, and instead of completely giving it back, it’s been consolidating around this area. That’s usually what I want to see after a sharp move. Not straight up every day, not some crazy squeeze that dies in two sessions, but digestion. Let the stock build a new base and let people decide if this is just a short-term trade or the beginning of a bigger re-rating. And on the company side, they keep quietly adding serious people around the business. AbCellera appointed Dr. Lynn Seely to the Board of Directors as an independent director. She has experience developing medicines across endocrinology, oncology, and women’s health, which is interesting because it also comes at a time when ABCL635 results are should be coming soon. I’m not saying the board appointment means anything specific for ABCL635. But the timing is interesting…
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 7:07 PM
$ABCL $ABCL 1. ABCL635 (undergoing phase 2 trials) - Dr. Seely famously served as CEO of Myovant Sciences, where she successfully commercialized Orgovyx and Myfembree for women's and men's health. 2. ABCL386 (targeting cancer) and a heavy focus on [T-cell engaging antibodies] Dr. Seely is the current CEO of Lyell Immunopharma (a CAR T cell oncology company) and previously took the block buster cancer drug Xtandi from first in human trials through to global regulatory approvals. 3. she has a history of high value biotech executions. she led Medivation up until its $14 billion acquisition by Pfizer. she also served as lead independent director for Blueprint Medicines prior to its $9.1 billion acquisition by Sanofi.
0 · Reply
DeMampCamp
DeMampCamp Jul. 7 at 7:05 PM
$ABCL Slight frustrating day, we know damn well if we were downgraded we'd be down heavily! We rarely get upgrades and once we do, which took everyone by surprise, we fall! Anyway, moving on and we'll see what the rest of the week has in store for us!
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 7:03 PM
$ABCL My long term $ABCL price target isn’t a definitive number. Its this:
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 7 at 6:45 PM
$ABCL Current Stock Price: $7.71 Contracts to trade: $8.0 ABCL Jul 17 2026 Call Entry: $0.45 Exit: $0.65 ROI: 44% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 6:25 PM
$ABCL Abcellera is the most bullish stock i see according to price action. Tight action on low volume preceded by price increase on high volume. $ABCL $XBI Abcellera shown with 2Day trend ribbon
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 6:22 PM
$ABCL With Benchmark upgrading from HOLD to BUY, we now have 100% alignment across analysts
0 · Reply
Latest News on ABCL
AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 20 hours ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 1 day ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 4 weeks ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 4 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 4 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 4 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 10 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


Stocktradesmoon
Stocktradesmoon Jul. 7 at 9:47 PM
$ABCL I believe that we will hear about the next molecule going into IND enabling studies during this meeting. So many puzzle pieces coming into place. I feel like the momentum is building and this will be a perfect time for it to continue.
0 · Reply
tranq19
tranq19 Jul. 7 at 8:47 PM
$ABCL https://investors.abcellera.com/news/news-releases/2026/AbCellera-to-Report-Second-Quarter-2026-Financial-Results-on-August-5-2026/default.aspx
0 · Reply
ETAlpha
ETAlpha Jul. 7 at 8:23 PM
$ABCL hitting the hot zone! Pullback inbound? We are straight inside the heavy resistance area at $8.46 - $10.23. The charts are screaming for a healthy breather here, so locking in partial profits at these levels makes absolute tactical sense. Don't chase it up-let the market cool down and hand us a cleaner, lower-risk buying opportunity on the next dip! Full risk management strategy and buy targets pinned on my profile.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 8:12 PM
$ABCL $ABCL is holding up surprisingly well after that big move. The stock ran hard, and instead of completely giving it back, it’s been consolidating around this area. That’s usually what I want to see after a sharp move. Not straight up every day, not some crazy squeeze that dies in two sessions, but digestion. Let the stock build a new base and let people decide if this is just a short-term trade or the beginning of a bigger re-rating. And on the company side, they keep quietly adding serious people around the business. AbCellera appointed Dr. Lynn Seely to the Board of Directors as an independent director. She has experience developing medicines across endocrinology, oncology, and women’s health, which is interesting because it also comes at a time when ABCL635 results are should be coming soon. I’m not saying the board appointment means anything specific for ABCL635. But the timing is interesting…
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 7:07 PM
$ABCL $ABCL 1. ABCL635 (undergoing phase 2 trials) - Dr. Seely famously served as CEO of Myovant Sciences, where she successfully commercialized Orgovyx and Myfembree for women's and men's health. 2. ABCL386 (targeting cancer) and a heavy focus on [T-cell engaging antibodies] Dr. Seely is the current CEO of Lyell Immunopharma (a CAR T cell oncology company) and previously took the block buster cancer drug Xtandi from first in human trials through to global regulatory approvals. 3. she has a history of high value biotech executions. she led Medivation up until its $14 billion acquisition by Pfizer. she also served as lead independent director for Blueprint Medicines prior to its $9.1 billion acquisition by Sanofi.
0 · Reply
DeMampCamp
DeMampCamp Jul. 7 at 7:05 PM
$ABCL Slight frustrating day, we know damn well if we were downgraded we'd be down heavily! We rarely get upgrades and once we do, which took everyone by surprise, we fall! Anyway, moving on and we'll see what the rest of the week has in store for us!
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 7:03 PM
$ABCL My long term $ABCL price target isn’t a definitive number. Its this:
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 7 at 6:45 PM
$ABCL Current Stock Price: $7.71 Contracts to trade: $8.0 ABCL Jul 17 2026 Call Entry: $0.45 Exit: $0.65 ROI: 44% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 6:25 PM
$ABCL Abcellera is the most bullish stock i see according to price action. Tight action on low volume preceded by price increase on high volume. $ABCL $XBI Abcellera shown with 2Day trend ribbon
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 6:22 PM
$ABCL With Benchmark upgrading from HOLD to BUY, we now have 100% alignment across analysts
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 7 at 6:18 PM
$ABCL Current Stock Price: $7.75 Contracts to trade: $8.0 ABCL Jul 17 2026 Call Entry: $0.50 Exit: $0.83 ROI: 65% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SultanK
SultanK Jul. 7 at 5:37 PM
$ABCL 2026-07-07 11:59:00 GMT DJ AbCellera Biologics Price Target Announced at $11.00/Share by Benchmark
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 7 at 4:09 PM
$ABCL $ABCL They gave you the positive news this morning and then they gave you the dip buy opportunity....I hope you took advantage of it like I did
1 · Reply
PorkchopSquats
PorkchopSquats Jul. 7 at 2:53 PM
$ABCL Hourly chart looks like a M-top forming. Needs to stay above $7.25ish else we will be seeing more good dip buys. Still like the company long term, just short-term observation.
0 · Reply
Amires
Amires Jul. 7 at 2:50 PM
$ABCL We’re way past the point where retail can move the needle here. Volume has 4x’d over the last year and keeps trending up 📈. This is now a heavyweight fight: Institutional Longs vs. Shorts. ​I guarantee the $7-$8 zone is where a lot of long-term retail holders got shaken out by short manipulation last time around. But it’s different this time. The shorts are going to get squeezed hard because these institutions know the game and they do not panic sell. 💎🙌 ​Bears are trapped. Get ready for the squeeze! 🚀🔥🍋
1 · Reply
Arnoldsens
Arnoldsens Jul. 7 at 2:49 PM
$ABCL This stock never can hold pre-market gains. Buy in after hours sell in the morning.
1 · Reply
Targhee
Targhee Jul. 7 at 1:50 PM
$ABCL ding…ding…ding - the ring of opportunity!
1 · Reply
DeMampCamp
DeMampCamp Jul. 7 at 1:47 PM
$ABCL Well that was certainly annoying, hope you penny flippers are all happy with your measly gains, the longs here are in this for the long haul!
0 · Reply
Ckkung71
Ckkung71 Jul. 7 at 1:43 PM
$ABCL Insane attack again in opening 😅
0 · Reply
GSP
GSP Jul. 7 at 12:46 PM
My latest gapper watch list for Tuesday (con't): $ABCL $FIG $PPCB $CCHH $SKYQ .
0 · Reply
Dovkav
Dovkav Jul. 7 at 12:42 PM
0 · Reply
DeMampCamp
DeMampCamp Jul. 7 at 12:23 PM
$ABCL Nice upgrade this morning, exciting times!
0 · Reply